Research Paper Volume 15, Issue 22 pp 12817—12851

Figure 7. Aberrantly expressed CBX2 and CEP55 as drug targets as pan-cancer level. (A) Summary of CBX2 and CEP55 expression pattern differences and their impact on tumor patient survival time (OS, DSS, DFI, PFI) across 21 cancers. Prognosis was inferred with hazard ratio, “risky” indicated HR > 1 whereas “protective” suggested HR < 1 (B) Summary of pathway activation or inhibition by CBX2 and CEP55 across 33 cancers. “Activation” represented significantly positive Spearman’s correlation conversely “Inhibition” indicated the significantly negative. (C) Kaplan-Meier plots of CBX2 expression in BRCA. High and Low groups were determined by the CBX2 expression cutoff computed by surv_cutpoint function in survminer package. P-value was computed with log-rank test. (D) Pearson’s correlation between the expression of CBX2 and CEP55 in BRCA, an example of pan-cancer. (E) Pearson’s correlation between the expression of CBX2 and CDKN1A with all tumors. OS, Overall Survival; DSS, Disease Specific Survival; DFI, Disease Free Interval; PFI, Progression Free Interval. (F) Pearson’s correlation of CBX2 and CDKN1A expression level in pan-cancer.